In the wake of Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest US$619m market cap drop, institutional owners may be forced to take severe actions

Simply Wall St.10-31

Key Insights Institutions' substantial holdings in Intellia Therapeutics implies that they have significant influence over the company's share price The top 10 shareholders own 51% of the company ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479799180?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2024-10-31 02:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479799180","market":"sg","top_or_hot":-1,"title":"In the wake of Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest US$619m market cap drop, institutional owners may be forced to take severe actions","media":"Simply Wall St.","content":"<div>\n<p>Key Insights  Institutions' substantial holdings in Intellia Therapeutics implies that they have significant influence over the company's share price   The top 10 shareholders own 51% of the company  ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/in-the-wake-of-intellia-therapeutics-incs-nasdaqntla-latest\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>In the wake of Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest US$619m market cap drop, institutional owners may be forced to take severe actions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIn the wake of Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest US$619m market cap drop, institutional owners may be forced to take severe actions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 02:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/in-the-wake-of-intellia-therapeutics-incs-nasdaqntla-latest><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Insights  Institutions' substantial holdings in Intellia Therapeutics implies that they have significant influence over the company's share price   The top 10 shareholders own 51% of the company  ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/in-the-wake-of-intellia-therapeutics-incs-nasdaqntla-latest\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/in-the-wake-of-intellia-therapeutics-incs-nasdaqntla-latest","article_id":"2479799180","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479799180","pubTimestamp":1730311952,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Key Insights Institutions' substantial holdings in Intellia Therapeutics implies that they have significant influence...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","QLD":"纳指两倍做多ETF","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","TQQQ":"纳指三倍做多ETF",".IXIC":"NASDAQ Composite","SQQQ":"纳指三倍做空ETF","PSQ":"纳指反向ETF","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU1861558580.USD":"日兴方舟颠覆性创新基金B","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4556":"基因编辑","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","QID":"纳指两倍做空ETF","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4535":"淡马锡持仓"},"translate_title":"Intellia Therapeutics,Inc.（纳斯达克股票代码：NTLA）最近市值下跌6.19亿美元后，机构所有者可能被迫采取严厉行动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1,"NDAQ":1,".IXIC":1,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Key Insights  Institutions' substantial holdings in Intellia Therapeutics implies that they have significant influence over the company's share price   The top 10 shareholders own 51% of the company    Recent sales by insiders    If you want to know who really controls Intellia Therapeutics, Inc. (NASDAQ:NTLA), then you'll have to look at the makeup of its share registry.  We can see that institutions own the lion's share in the company with 87% ownership.  Put another way, the group faces the maximum upside potential (or downside risk).  And institutional investors saw their holdings value drop by 29% last week.  The recent loss, which adds to a one-year loss of 40% for stockholders, may not sit well with this group of investors.   Also referred to as \"smart money\", institutions have a lot of sway over how a stock's price moves.  As a result, if the downtrend continues, institutions may face pressures to sell Intellia Therapeutics, which might have negative implications on individual investors.      In the chart below, we zoom in on the different ownership groups of Intellia Therapeutics.  See our latest analysis for Intellia Therapeutics NasdaqGM:NTLA Ownership Breakdown October 30th 2024 What Does The Institutional Ownership Tell Us About Intellia Therapeutics? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.   Intellia Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company.  This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong.  If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Intellia Therapeutics' earnings history below. Of course, the future is what really matters. NasdaqGM:NTLA Earnings and Revenue Growth October 30th 2024  Investors should note that institutions actually own more than half the company, so they can collectively wield significant power.    Hedge funds don't have many shares in Intellia Therapeutics.      ARK Investment Management LLC is currently the largest shareholder, with 11% of shares outstanding.       In comparison, the second and third largest shareholders hold about 9.4% and 9.0% of the stock.      Furthermore, CEO John Leonard is the owner of 0.8% of the company's shares.     We did some more digging and found that 10 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.    Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.   There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.  Insider Ownership Of Intellia Therapeutics The definition of an insider can differ slightly between different countries, but members of the board of directors always count.  The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.  I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.   We can see that insiders own shares in Intellia Therapeutics, Inc..   It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around US$21m worth of shares (at current prices).  If you would like to explore the question of insider alignment, you can  click here to see if insiders have been buying or selling.   General Public Ownership The general public-- including retail investors -- own 12% stake in the company, and hence can't easily be ignored.   While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.  Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Intellia Therapeutics better, we need to consider many other factors.    Consider for instance, the ever-present spectre of investment risk.   We've identified 2 warning signs  with Intellia Therapeutics , and understanding them should be part of your investment process.     But ultimately  it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.  NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479799180"}